Jacques Gonella Sold 200,000 Shares of Antares Pharma, Inc. (ATRS); CORBION NV ORDINARY SHARES (CSNVF) SI Decreased By 38.83%

CORBION NV ORDINARY SHARES (OTCMKTS:CSNVF) had a decrease of 38.83% in short interest. CSNVF’s SI was 12,600 shares in June as released by FINRA. Its down 38.83% from 20,600 shares previously. With 2,500 avg volume, 5 days are for CORBION NV ORDINARY SHARES (OTCMKTS:CSNVF)’s short sellers to cover CSNVF’s short positions. The SI to CORBION NV ORDINARY SHARES’s float is 0.02%. It closed at $31.640638 lastly. It is down 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Corbion N.V. operates as a food ingredients and biobased chemical firm worldwide. The company has market cap of $1.90 billion. The firm primarily offers lactic acid, lactic acid derivatives, and lactides, as well as emulsifiers, functional enzyme blends, minerals, and vitamins. It has a 17.87 P/E ratio. It also provides biobased products made from renewable resources and applied in various markets, such as bakery, meat, pharmaceuticals and medical devices, home and personal care, packaging, automotive, coatings, and adhesives.

The director of Antares Pharma Inc, Jacques Gonella a few days ago cashed-in exactly $546,000 U.S Dollars for 200,000 shares in the Antares Pharma Inc firm at an approx. $2.7 for share. It seems he is very active lately as in the last 30 days, he silently unloaded additional 1,500,000 shares of the company, worth $3,805,000 USD. Due to the significance of this sell, it will not go undiscovered. He owns 6.56% of the -company’s market cap with a total of 10.29 million shares. For complete information of this deal please read the Washington-based Security and Exchange Commission’s Form 4 ready for use here.

Since May 9, 2018, it had 0 insider buys, and 9 insider sales for $4.04 million activity. On Wednesday, May 16 the insider GONELLA JACQUES sold $507,000.

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma has $600 highest and $3.0 lowest target. $4.50’s average target is 54.64% above currents $2.91 stock price. Antares Pharma had 14 analyst reports since March 9, 2016 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Thursday, February 15. The company was maintained on Tuesday, October 10 by Jefferies. Jefferies maintained it with “Buy” rating and $3 target in Wednesday, March 9 report. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) earned “Buy” rating by H.C. Wainwright on Wednesday, March 14. As per Monday, October 23, the company rating was maintained by Piper Jaffray. The firm earned “Buy” rating on Tuesday, May 8 by H.C. Wainwright. Jefferies maintained the stock with “Buy” rating in Monday, August 7 report. The company was maintained on Monday, October 23 by H.C. Wainwright. The company was initiated on Friday, September 8 by H.C. Wainwright. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) earned “Buy” rating by Piper Jaffray on Tuesday, July 25.

Investors sentiment decreased to 0.8 in 2018 Q1. Its down 0.36, from 1.16 in 2017Q4. It worsened, as 15 investors sold Antares Pharma, Inc. shares while 26 reduced holdings. 10 funds opened positions while 23 raised stakes. 55.98 million shares or 2.75% more from 54.49 million shares in 2017Q4 were reported. Invesco has invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Guggenheim Capital Ltd Liability owns 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 530,246 shares. Legal & General Grp Public Limited Co invested in 25,894 shares or 0% of the stock. 130,000 were reported by M&T Commercial Bank. Tiaa Cref Inv Lc holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 340,657 shares. Ballentine Prns Llc reported 0.01% stake. Raymond James Financial Inc holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 148,046 shares. Credit Suisse Ag holds 0% or 50,417 shares in its portfolio. Tower Cap Ltd Liability Company (Trc) accumulated 832 shares. Armistice Capital Ltd Company invested in 12.56M shares. Goldman Sachs Gp reported 123,511 shares. State Common Retirement Fund holds 0% or 141,800 shares. Atlantic Tru Limited Company reported 0% stake. Great Point Ltd Limited Liability Company has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Us Natl Bank De holds 10,000 shares.

The stock increased 2.11% or $0.06 during the last trading session, reaching $2.91. About 1.06M shares traded or 9.56% up from the average. Antares Pharma, Inc. (NASDAQ:ATRS) has declined 4.71% since June 14, 2017 and is downtrending. It has underperformed by 17.28% the S&P500. Some Historical ATRS News: ; 30/05/2018 – Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET™ Needle-Free Delivery System; 27/03/2018 – ANTARES PHARMA -ANTICIPATES RESUBMISSION TO INCLUDE RE-ANALYSES OF EXISTING DATA, ADDRESS LABELING, POTENTIAL POST-APPROVAL RISK MITIGATION STRATEGIES; 27/03/2018 – Antares Capital Supports The Gores Group’s Recapitalization of TurbineAero, Inc; 27/03/2018 – ANTARES DOESN’T SEE ADDED TRIALS NEEDED TO SUPPORT RESUBMISSION; 27/03/2018 – ANTARES PHARMA INC – OFFICIAL MINUTES FROM TYPE A MEETING WITH FDA ON FEB. 21 HAVE BEEN RECEIVED; 16/03/2018 – FDA: New Drug Application (NDA): 204824 Company: ANTARES PHARMA INC; 15/05/2018 – Perceptive Advisors LLC Exits Position in Antares Pharma; 06/04/2018 – Antares Capital Supports Sentinel Capital Partners’ Acquisition of UBEO Business Services; 27/03/2018 – Antares Capital Supports The Gores Group’s Recapitalization of TurbineAero, Inc; 27/03/2018 – Antares Pharma Provides Xyosted Regulatory Update From FDA

Analysts await Antares Pharma, Inc. (NASDAQ:ATRS) to report earnings on August, 14. They expect $-0.02 earnings per share, 0.00% or $0.00 from last year’s $-0.02 per share. After $-0.04 actual earnings per share reported by Antares Pharma, Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

More recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Globenewswire.com which released: “Antares Pharma to Present at the Jefferies 2018 Healthcare Conference” on May 29, 2018. Also Seekingalpha.com published the news titled: “Antares Pharma: Excellent Risk-Reward Profile” on May 22, 2018. Nasdaq.com‘s news article titled: “Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJETâ„¢ Needle-Free Delivery System” with publication date: May 30, 2018 was also an interesting one.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart